Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAS Family Gene Mutation”

52 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 52 results

Early research (Phase 1)Ended earlyNCT07121829
What this trial is testing

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorPilocytic Astrocytoma+7 more
Day One Biopharmaceuticals, Inc. 44
Testing effectiveness (Phase 2)Looking for participantsNCT06206096
What this trial is testing

PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC

Who this might be right for
Colorectal CancerRAS MutationColorectal Neoplasms+1 more
Chinese PLA General Hospital 40
Testing effectiveness (Phase 2)Study completedNCT01927341
What this trial is testing

Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

Who this might be right for
Metastatic Colorectal Cancer
Pfizer 53
Testing effectiveness (Phase 2)Temporarily pausedNCT05756556
What this trial is testing

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Who this might be right for
MelanomaMalignant Melanoma
ImmVira Pharma Co. Ltd 68
Very early researchEnded earlyNCT03272633
What this trial is testing

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia in RemissionHematopoietic Cell Transplantation Recipient+16 more
Rutgers, The State University of New Jersey 2
Testing effectiveness (Phase 2)Looking for participantsNCT06229340
What this trial is testing

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Who this might be right for
RAS MutationRas (Kras or Nras) Gene MutationColorectal Cancer Recurrent+4 more
N.N. Petrov National Medical Research Center of Oncology 20
Early research (Phase 1)Looking for participantsNCT06299839
What this trial is testing

PAS-004 in Patients With Advanced Solid Tumors

Who this might be right for
RAS MutationNF1 MutationRAF Mutation+1 more
Pasithea Therapeutics Corp. 48
Testing effectiveness (Phase 2)Study completedNCT03271047
What this trial is testing

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Who this might be right for
MSSRAS-mutant Colorectal Cancer
Pfizer 75
Testing effectiveness (Phase 2)Looking for participantsNCT06321081
What this trial is testing

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Who this might be right for
RAS MutationMetastatic Colorectal CancerMSS
Beijing Hospital 60
Early research (Phase 1)WithdrawnNCT00837135
What this trial is testing

GI-4000 With Adoptive Transfer in Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
University of Pennsylvania
Not applicableUnknownNCT04852250
What this trial is testing

Centralized Tumour Board and Secondary Intervention Rate in mCRC

Who this might be right for
Metastatic Colorectal CancerRAS MutationMultidisciplinary Communication+1 more
Ludwig-Maximilians - University of Munich 130
Testing effectiveness (Phase 2)Study completedNCT05340621
What this trial is testing

NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Who this might be right for
RAS MutationNRAS Gene MutationMelanoma
OnKure, Inc. 36
Testing effectiveness (Phase 2)Looking for participantsNCT05727163
What this trial is testing

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

Who this might be right for
Colorectal Cancer Metastatic
Sun Yat-sen University 194
Not applicableStudy completedNCT02792478
What this trial is testing

Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study

Who this might be right for
RAS Wild Type mCRC
Amgen 238
Early research (Phase 1)Looking for participantsNCT04678648
What this trial is testing

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Who this might be right for
Advanced Malignant Solid NeoplasmRAS MutationLung Cancer+3 more
RasCal Therapeutics, Inc. 134
Early research (Phase 1)Looking for participantsNCT06884618
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

Who this might be right for
Neoplasms
Hoffmann-La Roche 345
Testing effectiveness (Phase 2)Looking for participantsNCT07397338
What this trial is testing

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Solid TumorsNon-small Cell Lung Cancer (NSCLC)+3 more
Revolution Medicines, Inc. 370
Large-scale testing (Phase 3)Looking for participantsNCT07252232
What this trial is testing

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc. 500
Testing effectiveness (Phase 2)Looking for participantsNCT06445062
What this trial is testing

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Who this might be right for
Colorectal CancerCRCPancreatic Ductal Adenocarcinoma+3 more
Revolution Medicines, Inc. 1,130
Testing effectiveness (Phase 2)Study completedNCT02448290
What this trial is testing

Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy

Who this might be right for
Gastric Adenocarcinoma
Samsung Medical Center 25
Load More Results